Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

ital to finance our Company. Further, management has been evaluating our programs, personnel and business strategies, and is currently working to reduce our financial commitments and, where necessary, rationalize certain programs though controlled spending and increased out-licensing efforts.

As previously announced, we plan to raise up to $2.5 million pursuant to a rights offering. Additional information concerning the rights offering will be provided by us in a forthcoming communication.

FINANCIAL RESULTS

For the three months ended July 31, 2008 ("Q1/09"), MIGENIX incurred a loss of $2.6 million (Q1/08: $3.1 million) or $0.03 (Q1/08: $0.03) per common share. The $0.5 million decrease in the Q1/09 loss compared to the Q1/08 loss is principally attributable to a $0.7 million decrease in research and development expenses, which was partially offset by a $0.2 million increase in accretion expense and a $0.1 million decrease in interest income. The accretion expense is a non-cash expense resulting from accreting the liability component of the convertible royalty participation units and amortizing the related deferred financing costs.

As of July 31, 2008, the Company had cash, cash equivalents and short- term investments of $3.6 million (April 30, 2008: $5.6 million) and the Company's net working capital was $3.3 million (April 30, 2008: $5.0 million). The $1.7 million decrease in net working capital from April 30, 2008 is primarily attributable to the $1.7 million in expenses for the three months ended July 31, 2008 that do not require the use of cash (i.e. non-cash expenses include:: amortization, stock-based compensation, deferred share unit compensation and the accretion of the convertible royalty participation units).

MIGENIX believes that its funds on hand at July 31, 2008 and $0.5 million in funds received in August 2008 from the July 31, 2008 government assistance receivable (see balance sheet), combined with ongoing cost reduc
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... 2014 BioElectronics Corporation (OTC Pink: ... devices said that its EVP Dr. ... as part of its Executive Interview Series. ... at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel In ... the unique advantages of BioElectronics patented technology ...
(Date:8/18/2014)... August 18, 2014 According ... Market Research "Life Science Reagents Market(Products- PCR Reagent ... Chromatography, In-Vitro Diagnostic Reagents and Others; End Users- ... Clinical Laboratories, and Forensic Laboratories)- Global Industry Analysis, ... 2019", the global life science reagents market was ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... from the nations nuclear weapons program lie in a ... Beneath this desert landscape about two million curies of ... are captured within the stratified vadose zone below which ... paths create uncertainties about where the contaminants go and ...
... - Researchers have developed a new modeling technique ... that could help industry perfect lab-on-a-chip technology for ... , The experimental devices represent a new class ... specific "target molecules," which will allow the sensors ...
... PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ --,WuXi PharmaTech ... of pharmaceutical R&D,outsourcing services, has signed a ... Inc. (AppTec). The acquisition of AppTec allows,WuXi ... expertise,gain a significant U.S. operational footprint, and ...
Cached Biology Technology:Where does stored nuclear waste go? 2Model is first to compare performance of 'biosensors' 2Model is first to compare performance of 'biosensors' 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 2WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 3WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 4WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc. 5
(Date:8/20/2014)... Washington , August 20, 2014 ... Concerns in the Payment Industry?   Investorideas.com ... including biometrics, issues commentary from analysts and experts on the ... Managing Partner at Thrive Analytics, Isabelle Moeller of ... NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ), a biometric company ...
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... 3 HIV vaccine efficacy trial are reported in the March ... online. Although the vaccine was ineffective in preventing HIV infection, ... and offers the scientific community a foundation on which to ... United States and the Netherlands and completed in 2003, is ...
... evidence in laboratory studies that the immune system may ... the drug through an unusual vaccine-like mechanism. Their finding, ... chronic users go on long binges with the illicit ... to new treatments for the drug's addiction, they say. ...
... access publishing and the NIH new policy from ... of Health (NIH) rule on Enhanced Public Access to ... and a missed opportunity to take advantage of available ... the nation's leading not-for-profit medical and scientific publishers. The ...
Cached Biology News:HIV vaccine trial breaks ground for future research 2Chemists identify immune system mechanism for methamphetamine binges 2Chemists identify immune system mechanism for methamphetamine binges 3Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
... Tracker Intracellular Localization Kit provides a straight ... siRNA, of your design, in an efficient ... experiments. Subcellular localization and functional inhibition of ... introduction of the labeled siRNA into mammalian ...
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
Biology Products: